ArticlePloS one2017

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Shinichiro Kashiwagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.